A prespecified subgroup analysis of an open-label, multicenter, single-arm, dose-titration study is presented. The efficacy and safety of 20-week treatment with an amlodipine (AML)/olmesartan medoxomil (OM) ± hydrochlorothiazide (HCTZ) algorithm were assessed in patients with hypertension and type 2 diabetes mellitus (T2DM) who were uncontrolled by antihypertensive monotherapy. Eligible patients received AML/OM 5/20 mg for 4 weeks, followed by stepwise uptitration to AML/OM 5/40 mg, AML/OM 10/40 mg, AML/OM 10/40 mg þ HCTZ 12.5 mg and AML/OM 10/40 mg þ HCTZ 25 mg at 4-week intervals if blood pressure (BP) remained uncontrolled. The primary end point was the achievement of the seated cuff systolic BP (SeSBP) goal (o140 mm Hg, or o130 mm Hg for patients with T2DM) at week 12. Seated cuff BP was significantly reduced from baseline at all titration dose periods. At week 12, the cumulative SeSBP goal was achieved by 57.9% and 80.1% of patients in the T2DM and non-T2DM subgroups, respectively. Treatment was well tolerated, with low rates of peripheral edema. In summary, switching to a treatment algorithm based on AML/OM ± HCTZ after failed monotherapy was safe and improved BP control in patients with hypertension and T2DM.
INTRODUCTION
Hypertension is a well-known risk factor for major cardiovascular (CV) outcomes, including myocardial infarction, stroke, and heart failure, 1 and is associated with substantial costs to the health-care system at an estimated $503.2 billion. 2 According to the most recent 10-year National Health and Nutrition Examination Survey data, blood pressure (BP) control in the United States has improved from 30.3% in 1999 to 48.4% in 2008, whereas hypertension prevalence has remained mostly steady at 30%. 3 However, coinciding with this steady prevalence of hypertension in the United States is an increase in the incidence of both obesity and diabetes mellitus. 4 An analysis of data from the National Health and Nutrition Examination Survey indicated that the prevalence of hypertension is much higher in patients with diabetes (77%). 5 This is of great concern because type 2 diabetes mellitus (T2DM) is associated with an increased risk of developing coronary heart disease. 6 Moreover, achieving BP control in patients with hypertension and comorbid diabetes can prove to be more difficult compared with hypertensive patients without this additional risk factor. 7 Clinical practice guidelines recommend a more stringent BP goal of o130/80 mm Hg for patients with diabetes. 8 The American Diabetes Association recommends that pharmacological treatment of hypertension in patients with diabetes should be initiated with a regimen that includes either an angiotensinconverting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB). 9 These guidelines also acknowledge that combination antihypertensive drug therapy may be necessary to achieve BP goals.
If combination therapy is needed, a rational antihypertensive drug combination is a renin-angiotensin system blocker, such as an ARB, plus a calcium channel blocker (CCB) . Both drug classes demonstrate good BP-lowering efficacy, with the additional benefit that the ARB component can minimize the development of peripheral edema, which is commonly seen with the use of CCBs through the vasodilatory effects of this drug class. Similarly, ARB/CCB combinations have also been associated with increased antihypertensive potency because of the benefit of complementary mechanisms of action. [10] [11] [12] As a result, the combination of a renin-angiotensin system blocker, such as an ACEI or ARB, with a CCB may be beneficial in patients with high metabolic risk. 13 The Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm study showed that the superior BP-lowering efficacy of a CCB/ACEI-based regimen was accompanied by a significant reduction in the risk of CV events, compared with a b-blocker/diuretic-based regimen in patients with hypertension and at least three additional CV risk factors.
14 Furthermore, the Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension study demonstrated that an ACEI/CCB regimen was superior to an ACEI/ hydrochlorothiazide (HCTZ) regimen for the reduction of the primary end point, a composite of CV death and CV events, in high-risk hypertensive patients. 15 ARB/CCB combinations have been shown to provide greater BP control than component monotherapies and a favorable tolerability profile, 16 but CV morbidity/mortality data is currently lacking for these combinations. Olmesartan medoxomil (OM), an ARB with a long history of use in clinical practice, has been shown to provide greater reductions in 24-h ambulatory BP monitoring (ABPM) than several other ARBs, despite similar reductions in office BP. 17 The BP Control in All Subgroups with Hypertension (BP-CRUSH; ClinicalTrials.gov identifier: NCT00791258) study assessed the antihypertensive efficacy and safety of a dose-titration regimen based on amlodipine (AML)/OM, with or without HCTZ, in patients whose hypertension was not controlled with previous antihypertensive monotherapy. This prespecified analysis of the BP-CRUSH study focuses on the difficult-to-treat subpopulations of patients with hypertension and T2DM. Efficacy data on patients with metabolic syndrome (MetS) are also presented.
MATERIALS AND METHODS

Study design
BP-CRUSH was a 20-week, phase IV (IIIb in South Africa) prospective, open-label, multicenter, single-arm, dose-titration study with a 20-week active treatment period. Details of the main study have been described previously. 18 Overall, 999 subjects underwent treatment with AML/OM combination therapy with or without add-on HCTZ for 20 weeks of duration after failing to achieve BP control on prior monotherapy for at least 1 month (Figure 1 ).
On day 1, patients who were uncontrolled on previous monotherapy were switched, without washout, to a fixed-dose combination of AML/OM 5/20 mg for 4 weeks, followed by uptitration to AML/OM 5/40 mg, AML/OM 10/40 mg, AML/OM 10/40 mg þ HCTZ 12.5 mg and AML/OM 10/40 mg þ HCTZ 25 mg at 4-week intervals (Figure 1 ). Patients were eligible for uptitration to any AML/OM dose combination if mean systolic BP (SBP) was X120 and o200 mm Hg, or mean diastolic BP (DBP) was X70 and o115 mm Hg. Patients were eligible to uptitrate to any dose, including an HCTZ add-on, if mean SBP was X125 and o200 mm Hg, or mean DBP was X75 and o115 mm Hg. Patients with adequately controlled BP were maintained at their current drug dose. If a patient's BP became uncontrolled (SBP X130 mm Hg or DBP X80 mm Hg), the patient received the next higher dose and reentered the titration scheme. Thus, efficacy analyses at the 12-week time point highlight the effect of treatment with AML/OM combination therapy, whereas analyses at the 20-week end point highlight the additional effects gained by triple combination therapy with AML/OM þ HCTZ.
Study population
Inclusion and exclusion criteria have been described in detail previously. 18 Briefly, male and female patients with hypertension and T2DM or MetS who were aged 18-80 years were included in this substudy. All patients had uncontrolled BP (mean SBP X140 and p180 mm Hg, or X130 and p180 mm Hg for patients with T2DM, and mean DBP p110 mm Hg at two consecutive screening visits) after at least 1 month of antihypertensive monotherapy with an ARB, CCB, ACEI, b-blocker or a diuretic. MetS was defined as patients who had three or more of the following: high-density lipoprotein cholesterol (o40 mg dl À 1 for men and o50 mg dl À 1 in women), triglycerides X150 mg dl À 1 , BP X130/85 mm Hg and fasting blood glucose X100 mg dl À 1 . Patients were excluded if they had T2DM requiring insulin or T2DM with glycosylated hemoglobin of X9.0% at screening.
BP measurements
Seated cuff BP (SeBP) measurements were taken using an Omron HEM-705CP automated BP monitor (Omron Corporation, Tokyo, Japan) at baseline (day 1), weeks 4, 8, 12, 16 and 20 . The mean of three SeBP measurements was used to determine if study subjects had reached BP goals.
ABPM was performed using the SpaceLabs 90207 oscillometric device (SpaceLabs Healthcare, Issaquah, WA, USA) and was initiated in the morning on day 1, week 12 and week 20 in a predetermined subset of the study population.
Efficacy variables
The primary efficacy end point of this prespecified analysis was the cumulative proportion of patients in the T2DM, non-T2DM or MetS subgroups who achieved the seated cuff SBP (SeSBP) target after switching from monotherapy to 12 weeks of treatment with AML/OM combination therapy. The target BP was defined as an SBP of o140 mm Hg (or o130 mm Hg for patients with diabetes). Secondary efficacy end points included an assessment of changes from baseline in mean SeSBP and seated cuff DBP (SeDBP) by the end of each titration dose period, an assessment of both the noncumulative and cumulative (see definitions below) percentage of patients achieving SeBP targets at each titration dose of AML/OM ± HCTZ, and an assessment of changes from baseline in mean ambulatory SBP and DBP to weeks 12 and 20 over 24 h, during the daytime (0800-1600 hours), nighttime (1000-1800 hours), and during the last 2, 4 and 6 h of the dosing interval.
Safety and tolerability assessments
Safety and tolerability were assessed by recording all adverse events (AEs), vital signs, standard clinical laboratory tests, physical examinations and electrocardiograms at baseline and throughout the course of the study. Two weeks after study conclusion, subjects were followed-up for AEs by telephone. A complete physical examination was also conducted at week 20 or upon early termination from the study. A post-hoc investigation into the effects on glycosylated hemoglobin resulting from the addition of HCTZ to AML/OM combination therapy at week 12 was also conducted.
Statistical analysis
The noncumulative BP target-achievement rate by visit was calculated as the ratio of the number of patients who achieved the target BP at the visit date over the number of patients with valid BP values at the visit date with the last observation before each visit carried forward. The noncumulative BP target-achievement rate was also assessed according to the titration dose and was defined similarly, with the 'visit' replaced by 'end of the titration dose period' value. The cumulative BP target-achievement rate by visit was calculated as the ratio of the number of patients who achieved the target at any time from the first dose date to the visit date over the number of patients who had any post-baseline BP data by that visit. The cumulative BP target-achievement rate according to the titration dose used (for example, AML/OM 5/20 or 5/40 mg) was defined similarly, with 'visit' replaced by 'end of the titration dose period.' Changes from baseline in SeBP and ABPM and dose-titration effects of the treatment algorithm on SeBP were summarized using descriptive statistics and analyzed by a one-sample paired t-test, with corresponding s.e. and 95% confidence intervals. Figure 7a for patients with T2DM. Ambulatory SBP was controlled throughout the 24-h dosing interval in patients with T2DM by week 20.
In patients without T2DM who underwent ABPM, the change in mean 24-h ambulatory BP was -15.0/-9.5 and -21.5/-13.6 mm Hg from a baseline of 136.1/81.6 and 136.1/81.7 mm Hg at weeks 12 and 20, respectively (Po0.0001) (Figures 5b and 6b ). Significant reductions from baseline were also seen for week 12 and week 20 during the daytime and nighttime intervals, as well as for the last 2 h (-13.8/-8.7 mm Hg (Po0.0001) and -20.3/-12.8 mm Hg (Po0.0001), respectively), 4 h (-13.2/-8.1 mm Hg (Po0.0001) and -18.8/-12.0 mm Hg (Po0.0001), respectively) and 6 h (-12.8/-7.7 mm Hg (Po0.0001) and -18.4/-11.6 mm Hg (Po0.0001), respectively) of the dosing interval. Mean hourly ambulatory SBP levels at baseline, week 12 and week 20 are summarized in Figure 7b for patients without T2DM. Ambulatory SBP was controlled throughout the 24-h dosing interval in patients without T2DM by week 20. Figures S4A and B) . Similar to patients with T2DM, significant reductions from baseline were also observed over the daytime and nighttime intervals at weeks 12 and 20. These BP reductions were also maintained through the last 2, 4 and 6 h of the dosing interval at weeks 12 (-11.9/-8.6, -11.5/-8. Efficacy of AML/OM in patients with T2DM or MetS SD Nesbitt et al Safety Overall, the treatment regimen was well tolerated. In the total T2DM subgroup (n ¼ 192), 100 patients (52.1%) experienced a treatment-emergent AE (TEAE) during the study, including 47 patients (24.5%) with a drug-related TEAE ( Table 2 ). The one reported serious TEAE was not drug-related. Drug-related TEAEs usually associated with the study medication occurred at low frequencies and included dizziness (7.8%), peripheral edema (4.2%), hypotension (2.1%) and headache (1.6%) ( Table 3) . Peripheral edema was not reported in patients with T2DM who were uptitrated to HCTZ, and there were no reported incidences of edema in any treatment group. In the non-T2DM patient subgroup (n ¼ 807), 429 patients (53.2%) experienced a TEAE during the study, including 208 patients (25.8%) reporting a drug-related TEAE (Table 2 ). Eleven patients (1.4%) reported a serious TEAE and none were considered to be drug-related. Similar to the T2DM subgroup, drug-related TEAEs usually associated with the study medication occurred at Efficacy of AML/OM in patients with T2DM or MetS SD Nesbitt et al low frequencies and included dizziness (7.6%), peripheral edema (7.1%), hypotension (2.4%) and headache (2.l%). Peripheral edema occurred at low incidences for all doses but decreased to 0.0% with the addition of HCTZ.
The proportions of patients experiencing a TEAE, drug-related TEAE or serious TEAE in the MetS subgroup were similar to those reported for the T2DM and non-T2DM subgroups (Supplementary  Table S1 ).
DISCUSSION
The findings of this prespecified subgroup analysis of the BP-CRUSH study demonstrate that an AML/OM-based titration regimen effectively enables BP reductions and the achievement of BP goals in patients with hypertension, with or without T2DM, who were uncontrolled on previous antihypertensive monotherapy. Significant reductions from baseline in SeBP were seen for all titration dose periods in the T2DM and non-T2DM patient subgroups. Moreover, the greatest BP reductions were seen in patients who received AML/OM þ HCTZ, which indicate that the addition of HCTZ to a fixed-dose ARB/CCB combination can further improve BP-lowering efficacy. The treatment regimen used in BP-CRUSH was also effective in a subgroup of patients with MetS, enabling the majority of these patients to achieve their recommended BP goal.
The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure guidelines recognize that the majority of patients with hypertension will require at least two antihypertensive agents to achieve BP goals, and thus recommend the use of a stepwise approach for treatment. 8, 19 This is particularly important in patients who are at high risk of CV events, such as those with T2DM or MetS; 6, 20, 21 these patients will often require more intense and aggressive therapeutic strategies to achieve BP control. 19, 22 In the current analysis, an SeBP goal of o130/80 mm Hg was achieved by approximately 33% of the patients in the T2DM subgroup at the maximum dual-combination therapy dose, which is similar to observational data from the most recent National Health and Nutrition Examination Survey, showing BP control rates of 35.3% in patients with T2DM. 5 Moreover, the addition of HCTZ to the treatment regimen enabled 44% of patients with T2DM to achieve BP control after uptitration to the 25-mg dose. For patients without T2DM, a majority of these patients (that is, 76%) were able to achieve their comparably less-stringent recommended SeBP goal of o140/90 mm Hg at this same maximum dose. The higher BP goal achievement rates in the non-T2DM subgroup were associated with larger decreases in SeBP compared with patients with T2DM. However, the actual SeBP reductions in the T2DM patient subgroup were comparable to the large reductions observed in the non-T2DM patient subgroup at the maximum study dose (that is, -24.2/-13.0 vs -25.3/-13.9 mm Hg, respectively).
In the MetS subgroup, approximately 79% of patients achieved the noncumulative SeSBP goal of o140/90 mm Hg. Similar to the T2DM subgroup, achievement of the SeBP threshold of o140/ 90 mm Hg showed an increasing trend with treatment intensification. These results appear to be similar to, or higher than, rates reported in other studies that uptitrated from inadequate monotherapy to combination therapy with AML/OM. 23, 24 Increasing evidence suggests that 24-h ambulatory BP may be a better predictor of patient outcomes compared with office BP measurements. 25 This enables the clinician to observe the antihypertensive effects of a drug across the dosing period, 25, 26 especially during the early morning hours when there is a surge in BP levels, which is associated with an increase in CV events. 27, 28 In the current analysis, ABPM data at week 20 indicated that ambulatory BP was consistently reduced in both T2DM and non-T2DM subgroups during the 24-h, daytime and nighttime periods. Mean ambulatory BP remained o130/80 mm Hg throughout the dosing interval. Furthermore, because AML/OM ± HCTZ was administered in the morning, ambulatory BP changes during the last 2, 4 and 6 h of the dosing period reflect medication effects on the early morning BP surge. AML/OM was safe and well tolerated even when titrated to maximum doses with or without maximum doses of add-on HCTZ. In general, no new safety issues were observed in the T2DM subgroup, and tolerability profiles were similar when compared with the non-T2DM subgroup. The incidence of peripheral edema was low in both subgroups and its incidence decreased with add-on HCTZ. This finding was consistent with data from previous studies that investigated AML/OM combination therapy 10, 29 or the combination of other renin-angiotensin system inhibitors with AML. 11 It has been suggested that combining antihypertensive medications with different mechanisms of action, such as an ARB (OM) and a dihydropyridine CCB (AML), may ameliorate adverse effects that are specific for component monotherapies. 13, 30 It is noteworthy that the incidence of hypotension was also low, even with the addition of HCTZ to AML/OM combination therapy.
A number of study limitations should be highlighted. The openlabel, single-arm design has an inherent potential for investigator and patient bias. Furthermore, the total treatment period of 20 weeks is relatively short, compared with previously reported longterm studies assessing AML/OM ± HCTZ. 29, 31 Despite these limitations, it should be noted that the design of the BP-CRUSH study is unique in that it allowed for the inclusion of patients on monotherapy with a variety of different classes of antihypertensives at baseline. This is reflective of real-world clinical practice, wherein physicians may receive new patients on medications that they would not normally prescribe and then find it necessary to revise or optimize their treatment regimen.
In conclusion, switching from failed monotherapy to a treatment regimen based on AML/OM±HCTZ was well tolerated and improved the achievement of BP goals in patients with hypertension, irrespective of diabetic status or presence of MetS. This suggests that such a treatment algorithm may be an effective treatment option in difficult-to-treat patient populations, particularly those with T2DM or MetS who are inadequately controlled by treatment with a single antihypertensive agent.
What is known about this topic
Hypertension is a well-known risk factor for major cardiovascular outcomes, including myocardial infarction, stroke and heart failure. The prevalence of hypertension is much higher in patients with diabetes mellitus or metabolic syndrome (MetS). Both type 2 diabetes mellitus (T2DM) and MetS are associated with an increased risk of developing coronary heart disease. Achieving blood pressure (BP) control in patients with hypertension and T2DM or MetS can prove to be more difficult compared with hypertensive patients without these additional risk factors. According to current European guidelines for the management of HTN, patients with elevated BP or MetS should be treated with combinations of a renin-angiotensin system blocker and a low-dose thiazide diuretic or calcium channel blocker (CCB), which may help to reduce the progression of MetS to T2DM. Angiotensin receptor blocker/CCB combinations have been associated with increased antihypertensive potency because of complementary mechanisms of action and may be beneficial in patients with high metabolic risk.
What this study adds
The BP Control in All Subgroups with Hypertension (BP-CRUSH) study assessed the antihypertensive efficacy and safety of a dose-titration regimen based on amlodipine/olmesartan medoxomil (AML/OM), with or without hydrochlorothiazide (HCTZ), in patients whose hypertension was not controlled with prior antihypertensive monotherapy, and this prespecified analysis focused on the subpopulations of patients with hypertension and T2DM or MetS.
In patients with hypertension and T2DM or MetS, switching from failed monotherapy to a treatment regimen based on AML/OM ± HCTZ was well tolerated and improved the achievement of BP goals. Such a treatment algorithm may be an effective treatment option in difficult-to-treat patient populations, particularly those with T2DM or MetS, who are inadequately controlled by treatment with a single antihypertensive agent. The total number of patients with an AE may not match the sum of the individual titration steps because a single patient could experience the same event at X1 titration step.
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